Become a Private Equity Investor Partner
in KICMedDevices, LP
Investment Strategy & Target Allocation
This Growth and Buyout Medical Device Fund has identified six target investments ($5M-$10M each)
- Three Growth Targets: SpineFrontier, AxioMed and M&K Engineering which have strong operations
- Three M&A Targets: revenue generating distributorships
Objective: Raise $50M
|GP Capital Commitment
|Carried Interest Split
||85% to LP and 15% to GP
||1.5% of committed capital
Definitions: Limited Partnership (LP); General Partnership (GP)
KICVentures, LLC (“KICV”) is providing this website for informational purposes only. Nothing on this website is intended to constitute, or should be deemed to be, financial advisory, legal, tax, accounting or other professional advice to you or any other party, be an opinion of the appropriateness or suitability of any investment, or constitute an offer to sell or solicitation of an offer to buy any security or investment. This website and its content (collectively, “Content”) is intended for general informational purposes only and should not be acted upon without first obtaining financial advisory, legal, tax, accounting or other professional advice. KICV is the General Partner of KICMedDevices, LP (the “Fund”), a private investment fund being organized in Delaware in 2017. KICV is not registered as an investment adviser with the Securities and Exchange Commission (“SEC”) or with any state securities agency. The limited partnership interests (the “Interests”) in the Fund are offered under a separate confidential private placement memorandum, have not been registered under the Securities Act of 1933, as amended, or any state’s securities laws, and are sold for investment only pursuant to an exemption from registration with the SEC and in compliance with any applicable state or other securities laws. An investment in the Fund involves risk factors that should be reviewed carefully by potential investors and potential conflicts of interests are inherent in KICV’s management of the Fund. There is no assurance that the Fund will meet its investment objective.
© Copyright 2016. All Rights Reserved.